LIQUID BIOPSY, cfDNA, EGFR
`12500

Patients positive for EGFR mutations benefit from Tyrosine kinase inhibitors. This test uses Whole blood as the specimen (Liquid Biopsy) to detect mutations in Exon 19 (E746_A750del), Exon 20 (T790M) and Exon 21 (L858R). T790M mutation is a resistance mutation which benefits from third generation TKI's like Osimertinib.

  • Test Type:
  • Pre-test Information:
  • Report Delivery:
    Sample Mon / Thu 9 am; Report Fri / Tue Sample Mon / Thu 9 am; Report Fri / Tue Sample Mon / Thu 9 am; Report Fri / Tue
  • Components:
    0